Does Etanercept biosimilar prescription in a rheumatology center bend the medication cost curve?

CONCLUSION: The average cost per patient treated with biologicals decreased after the introduction of biosimilars with a persistent trend. However, the budgetary relief due to market entry of biosimilars vanished quickly due to an increase in patients treated with biologics. PMID: 33132223 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research